Compare · NTRA vs TRUP
NTRA vs TRUP
Side-by-side comparison of Natera Inc. (NTRA) and Trupanion Inc. (TRUP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTRA and TRUP operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $56.90B, about 48.5x TRUP ($1.17B).
- Over the past year, NTRA is up 116.9% and TRUP is down 33.5% - NTRA leads by 150.4 points.
- NTRA has been more active in the news (11 items in the past 4 weeks vs 4 for TRUP).
- NTRA has more recent analyst coverage (25 ratings vs 13 for TRUP).
- Company
- Natera Inc.
- Trupanion Inc.
- Price
- $391.71-3.21%
- $28.25+1.33%
- Market cap
- $56.90B
- $1.17B
- 1M return
- +6.97%
- +10.09%
- 1Y return
- +116.94%
- -33.48%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 11
- 4
- Recent ratings
- 25
- 13
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Trupanion Inc.
Trupanion, Inc., together with its subsidiaries, provides medical insurance for cats and dogs on monthly subscription basis in the United States, Canada, Puerto Rico, and Australia. The company operates through Subscription Business and Other Business segments. It serves pet owners and veterinarians. The company was formerly known as Vetinsurance International, Inc. changed its name to Trupanion, Inc. in 2013. Trupanion, Inc. was founded in 2000 and is headquartered in Seattle, Washington.
Latest NTRA
- Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026
- Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
- SEC Form 4 filed by Natera Inc.
- FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay
- Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
- New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
- Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $1,242,645 worth of shares (3,000 units at $414.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 106,914 units (SEC Form 4)
- CEO AND PRESIDENT Chapman Steven Leonard sold $526,144 worth of shares (1,273 units at $413.31) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 96,926 units (SEC Form 4)
- CO-FOUNDER Sheena Jonathan sold $7,008,972 worth of shares (18,064 units at $388.01) as part of a pre-agreed trading plan (SEC Form 4)
Latest TRUP
- Picture Purrfect Pets: Trupanion Announces 2026 truFame Winners
- SEC Form 4 filed by Trupanion Inc.
- A Partnership for Pets: Simon Cowell and Trupanion Team Up
- Chief Operating Officer Gallagher John R sold $9,879 worth of shares (431 units at $22.92) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 33,311 units (SEC Form 4)
- CEO Tooth Margaret sold $25,000 worth of shares (1,000 units at $25.00) as part of a pre-agreed trading plan, decreasing direct ownership by 0.53% to 185,952 units (SEC Form 4)
- Trupanion Searches for this Year’s “It Pets” With Return of Annual truFame Contest
- Chief Operating Officer Gallagher John R sold $107,039 worth of shares (3,604 units at $29.70) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 33,742 units (SEC Form 4)
- CEO Tooth Margaret converted options into 19,042 shares, covered exercise/tax liability with 7,000 shares and sold $15,633 worth of shares (491 units at $31.84), increasing direct ownership by 7% to 186,952 units (SEC Form 4) (withholding tax)
- Director Rubin Howard E converted options into 420 shares, increasing direct ownership by 0.18% to 233,288 units (SEC Form 4)
- Director Powell Bradley S converted options into 1,640 shares, increasing direct ownership by 86% to 3,546 units (SEC Form 4)